Table 3.
Evaluation of HE4, CA 125 and ROMA efficacy in the determination of the risk of ovarian cancer (including only patients with benign gynaecological diseases and ovarian cancer)
| Sensitivity | Specificity | PPV | NPV | Efficacy | Youden indices | ||
|---|---|---|---|---|---|---|---|
| HE4 | 88/111 (79.3%) | 282/285 (98.9%) | 88/91 (96.7%) | 282/305 (92.5%) | 370/396 (93.4%) | 0.782 | |
| CA 125 | 92/111 (82.9%) | 202/285 (70.9%) | 92/175 (52.6%) | 202/221 (91.4%) | 294/396 (74.2%) | 0.538 | |
| ROMA | 100/111 (90.1%) | 250/285 (87.7%) | 100/135 (74%) | 250/261 (95.8%) | 350/396 (88.4%) | 0.778 | |
| Premenopausal | HE4 | 17/27 (63%) | 226/226 (100%) | 17/17 (100%) | 226/236 (95.8%) | 243/253 (90.9%) | 0.63 |
| CA 125 | 20/27 (74.1%) | 156/226 (69%) | 20/90 (22.2%) | 156/163 (95.7%) | 176/253 (69.6%) | 0.431 | |
| ROMA | 20/27 (74.1%) | 201/226 (88.9%) | 20/45 (44.4%) | 201/208 (96.6%) | 221/253 (87.4%) | 0.630 | |
| Postmenopausal | HE4 | 71/84 (84.5%) | 56/59 (94.9%) | 71/74 (96%) | 56/69 (81.2%) | 127/143 (88.8%) | 0.794 |
| CA 125 | 72/84 (85.7%) | 46/59 (78.0%) | 72/85 (84.7%) | 46/58 (79.3%) | 118/143 (82.5%) | 0.637 | |
| ROMA | 80/84 (95.2%) | 49/59 (83.1%) | 80/90 (88.9%) | 49/53 (92.5%) | 129/143 (90.2%) | 0.841 | |
PPV positive predictive value; NPV negative predictive value